ArticleAging2020
Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells.
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 58 citations in OpenAlex.
- ZnO@PDA@Ag nanocomposite-mediated delivery of 9-bromonoscapine, an anticancer agent, for enhanced lung cancer therapy.Nanoscale advances · 2026Article
- Evaluating the mechanisms and therapeutic potential of ZnO nanoparticles as selective anticancer agents for lung malignancies.Discover nano · 2026Review
- Crossroads of iron, copper, and zinc in cancer: a paradox of toxicity and therapy.Molecular biology reports · 2026Review
- Bio-mediated synthesis of zinc oxide nanoparticles from Crossandra infundibuliformis leaves: A potent inducer of apoptosis in lung cancer cells.Medical oncology (Northwood, London, England) · 2026Article
- Thymoquinone loaded zinc oxide Nanoformulations synthesis, characterization and evaluation of their efficacy against carbon tetrachloride induced Hepatorenal toxicity in rats.Toxicology research · 2025Article
- ZnO nanoparticles induce acute arrhythmia and heart failure in mice by disturbing cardiac ion channels.Frontiers in cardiovascular medicine · 2025Article
- Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025Review
- Synthesis of F127-GA@ZnO nanogel as a cisplatin drug delivery pH-sensitive system.RSC advances · 2024Article
- Zinc Oxide Nanoparticles and Cancer Chemotherapy: Helpful Tools for Enhancing Chemo-sensitivity and Reducing Side Effects?Biological trace element research · 2024Review
- Impact of peripheral blood mononuclear cells preconditioned by activated platelet supernatant in managing gastric mucosal damage induced by zinc oxide nanoparticles in rats.Anatomy & cell biology · 2024Article
- Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer.Molecules (Basel, Switzerland) · 2024Review
- Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.Frontiers in immunology · 2024Review
- Zinc oxide nanoparticles inhibit malignant progression and chemotherapy resistance of ovarian cancer cells by activating endoplasmic reticulum stress and promoting autophagy.Experimental and therapeutic medicine · 2023Article
- Recent Advances in ZnO Nanomaterial-Mediated Biological Applications and Action Mechanisms.Nanomaterials (Basel, Switzerland) · 2023Review
- The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment.Frontiers in immunology · 2023Review
- Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments.Pharmaceutics · 2022Review
- Development of Ag-ZnO/AgO Nanocomposites Effectives forPharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is one of the most common malignancies worldwide. The use of a combination of chemotherapy drugs and zinc oxide nanoparticles (ZnO-NPs), which have proven to induce tumor-selective cell death, reduce the drug resistance and reduce the side effects
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.